SI
FATE icon

Sofinnova Investments’s Fate Therapeutics FATE Stock Holding History

Sofinnova Investments’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-46,386
Closed -$4.03M – 77
2021
Q2 		$4.03M Sell
46,386
-8,409
-15% -$678K 0.23% 55
2021
Q1 		$4.52M Buy
54,795
+41,298
+306% +$3.96M 0.27% 50
2020
Q4 		$1.23M Sell
13,497
-27,903
-67% -$1.73M 0.07% 62
2020
Q3 		$1.65M Buy
+41,400
New +$1.45M 0.12% 63
2020
Q2 		– Sell
-36,564
Closed -$812K – 81
2020
Q1 		$812K Sell
36,564
-598,579
-94% -$15.1M 0.08% 62
2019
Q4 		$12.4M Buy
635,143
+253,543
+66% +$4.03M 0.9% 25
2019
Q3 		$5.93M Buy
+381,600
New +$7.31M 0.54% 40
2019
Q2 		– Sell
-203,742
Closed -$3.58M – 75
2019
Q1 		$3.58M Sell
203,742
-26,071
-11% -$412K 0.35% 47
2018
Q4 		$2.95M Buy
229,813
+124,922
+119% +$1.74M 0.37% 47
2018
Q3 		$1.71M Buy
+104,891
New +$1.24M 0.15% 53

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Sofinnova Investments's FATE Position: Q3 2021 in Review

Sofinnova Investments sold out of Fate Therapeutics (FATE) in Q3 2021, closing a stake of 46,386 shares — an estimated $4.03M sold.

Sofinnova Investments first reported a position in FATE in Q3 2018 and held it in 10 quarters. The position peaked at $12.4M in Q4 2019. 265 funds tracked by Wall St. Rank hold FATE as of Q3 2021.

  • Sofinnova Investments reported no remaining Fate Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Sofinnova Investments sold 46,386 Fate Therapeutics shares in Q3 2021, an estimated $4.03M.
  • Sofinnova Investments first reported a position in Fate Therapeutics in Q3 2018 and held it in 10 quarters.
  • Sofinnova Investments's Fate Therapeutics position peaked at $12.4M in Q4 2019.
  • 265 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2021.

Based on Sofinnova Investments's 13F filing for Q3 2021, filed 15 Nov 2021.